Morgan Stanley Akebia Therapeutics, Inc. Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
A detailed history of Morgan Stanley transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 5,339,654 shares of AKBA stock, worth $17.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,339,654
Previous 2,681,198
99.15%
Holding current value
$17.7 Million
Previous $5.15 Million
277.62%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding AKBA
# of Institutions
171Shares Held
105MCall Options Held
134KPut Options Held
262K-
Vanguard Group Inc Valley Forge, PA14.6MShares$48.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$38.6 Million0.0% of portfolio
-
State Street Corp Boston, MA8MShares$26.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.07MShares$20.2 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$19.1 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $610M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...